Mast Cell Activation and Dysbiosis: Key Roles in Common GI Disorders
Functional gastrointestinal (GI) disorders such as irritable bowel syndrome and functional dyspepsia is thought to affect at least 15% of the general population. Mast cell activation and dysbiosis are among the leading pathophysiological processes that have been implicated in functional GI disorders featuring common symptoms such as bloating, abdominal pain, and altered bowel habits.
Advanced stool testing with quantitative PCR (qPCR) can provide important insights into overall gut health, as well as specific factors that may be involved in functional GI disorders.
Join Dr. Fabian October 20, 2021, at 2 PM ET as he discusses how GI-MAP stool testing can provide clinicians with critical insights into specific microbes, dysbiosis patterns, and GI imbalances that may contribute to mast cell activation and related symptoms in patients with functional GI disorders.
Thomas Fabian, PhD, CNTP
Tom is a leading expert on the role of the human microbiome in health, chronic disease, and aging. As a translational scientist, his primary focus is on the clinical application of research in the areas of the microbiome and mucosal immunology in the functional and integrative medicine space. He has worked with early-stage biotechnology companies as a research scientist, and more recently, as a consultant for microbiome and clinical testing companies, including Diagnostic Solutions Laboratory. He also serves as a scientific advisor for nutraceutical company Designs for Health. In addition, Tom provides consulting and educational services for functional medicine and integrative health practitioners. His doctoral training at the University of Colorado, Boulder, and postdoctoral training at the University of Utah were focused on the molecular biology of aging and longevity. He is also certified as a Nutrition Therapy Practitioner by the Nutrition Therapy Institute in Denver.
Thank you for downloading!